Inogen - INGN Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View INGN analyst ratings or view top-rated stocks.

3 Wall Street analysts have issued 12-month price targets for Inogen's shares. Their INGN share price forecasts range from $22.00 to $36.00. On average, they anticipate the company's share price to reach $29.33 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price.
View analysts price targets for INGN or view top-rated stocks among Wall Street analysts.

Inogen's stock was trading at $19.71 at the beginning of 2023. Since then, INGN stock has increased by 15.6% and is now trading at $22.78.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our INGN earnings forecast.

Inogen will be holding an earnings conference call on Thursday, February 23rd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13735129".

Inogen, Inc. (NASDAQ:INGN) posted its quarterly earnings results on Wednesday, November, 2nd. The medical technology company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.23. The medical technology company earned $105.39 million during the quarter, compared to analyst estimates of $97.57 million. Inogen had a negative trailing twelve-month return on equity of 11.02% and a negative net margin of 13.69%.

Inogen issued an update on its fourth quarter 2022 earnings guidance on Tuesday, January, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $87.50 million-$88.50 million, compared to the consensus revenue estimate of $89.55 million.

70 employees have rated Inogen Chief Executive Officer Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among the company's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.31%), Investment Management of Virginia LLC (0.12%), Yousif Capital Management LLC (0.06%), Comerica Bank (0.06%) and Strs Ohio (0.04%). Insiders that own company stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Holdings A/S Novo, Ray Benjamin M Anderson and Raymond Huggenberger.
View institutional ownership trends.

Shares of INGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INGN stock can currently be purchased for approximately $22.78.

Inogen (NASDAQ:INGN) has a market capitalization of $522.14 million and generates $358 million in revenue each year. The medical technology company earns $-6,330,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis.

The company employs 1,021 workers across the globe.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The official website for the company is www.inogen.com. The medical technology company can be reached via phone at (805) 562-0500 or via email at mpigeon@inogen.net.